Inotiv Reports Second Quarter Financial Results for Fiscal 2024 and Provides Business Update — Second quarter fiscal 2024 revenue down 21.5% to $119.0 million— Year-to-date fiscal 2024 revenue down 7.2% to $254.5 million— Agreement in principle reached with the U.S. Department of Justice on...

Inotiv, Inc. to Report Fiscal 2024 Second Quarter Financial Results and Host Conference Call on Wednesday, May 15, 2024 WEST LAFAYETTE, Ind., May 14, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical...

Inotiv, Inc. Reschedules its Fiscal 2024 Second Quarter Results WEST LAFAYETTE, Ind., May 09, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company”), a leading contract research organization specializing in nonclinical and analytical drug discovery...

Inotiv, Inc. to Report Fiscal 2024 Second Quarter Financial Results and Host Conference Call on Friday, May 10, 2024 WEST LAFAYETTE, Ind., April 29, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical...

Inotiv Reports First Quarter Financial Results for Fiscal 2024 and Provides Business Update - First quarter fiscal 2024 revenue up 10.3% to $135.5 million - First quarter fiscal 2024 DSA revenue up 8.8% to $44.7 million and RMS revenue up 11.1% to $90.8 million - Shift to a renewed focus...